Applicants: Mathias LOCHER et al.

Application No.: 10/523,802

Attorney Docket No. 42804-212835

## AMENDMENTS TO THE CLAIMS:

The following listing replaces all prior versions of the claims:

1-16. (Canceled)

17. (Previously presented) A method for the treatment and prophylaxis of respiratory diseases,

allergic diseases, asthma and/or chronic obstructive pulmonary diseases comprising the step of

administering loteprednol or a pharmaceutically acceptable ester thereof and N-(3,5-

dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or a

pharmaceutically acceptable salt thereof to a subject in need of treatment.

18. (Previously presented) The method as claimed in claim 17, wherein administration is oral.

19. (Previously presented) The method as claimed in claim 17, wherein administration is topical.

20. (Previously presented) The method as claimed in claim 17, wherein the loteprednol or

pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-

fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt

thereof are administered simultaneously, sequentially or separately from one another,

intranasally or by inhalation.

21. (Previously presented) The method as claimed in claim 17, wherein the loteprednol or

pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-

fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt

thereof are administered as an inhalable liquid or solid preparation.

22. (Previously presented) The method as claimed in claim 17, wherein one of the loteprednol or

pharmaceutically acceptable ester thereof and N-(3,5-dichloropyridin-4-yl)-2-[1-(4-

fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt

thereof is administered orally and one is administered topically.

2

Applicants: Mathias LOCHER et al.

Application No.: 10/523,802 Attorney Docket No. 42804-212835

23. (Previously presented) The method as claimed in claim 17, wherein the N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or pharmaceutically acceptable salt thereof is administered orally.